Glenmark Pharma at ₹2,270: Chartists Set ₹2,500 Target

Glenmark Pharmaceuticals shares traded at ₹2,270 on Thursday, holding above a support cluster between ₹2,220 and ₹2,180 that has contained selling pressure over the past several sessions. The stock has now bounced off that zone, and the recent price action suggests the corrective phase that started earlier in the month may have run its course.

Traders are positioning for a move toward ₹2,500, a level that would represent a roughly 10% gain from current prices. The pattern is built on a clear trendline support that has held through the pullback, giving the rally room to extend. A break below the ₹2,180 support floor, however, would invalidate the bullish reading and put the stock back in a range.

For those looking to join the move, entry at the current ₹2,270 level is one option. A more cautious approach would be to accumulate on any dip to ₹2,240, staying inside the support zone. The stop-loss sits at ₹2,130, which keeps risk manageable if the support fails. A trailing stop strategy can lock in gains: raise the stop to ₹2,295 once the stock hits ₹2,330, then to ₹2,360 at ₹2,410, and to ₹2,420 at ₹2,440. The recommended exit is at ₹2,480, just below the target.

The ₹2,500 target is not new. AlphaScala earlier outlined a similar setup based on the same support structure. What has changed is the price action–the stock has now confirmed the level by rallying off it, giving the pattern more weight.

Volume data is light for the session, which is typical for consolidation phases. A pickup in turnover on a breakout above ₹2,330 would confirm renewed buying interest. Until then, the setup remains intact but unconfirmed above the resistance zone.

The recommendation is based on technical analysis and carries standard trading risks. A stop-loss discipline is essential, as a break below ₹2,130 would shift the near-term picture back to neutral.